Biomedicines (Mar 2024)

Cardiotoxic Effects Produced by Omeprazole and Methylene Blue in an Animal Model of Cardiac Ischemia and Reperfusion and Potential Implications for the Pharmacological Strategy for Vasoplegic Syndrome

  • Erisvaldo Amarante de Araújo,
  • Fernando Sabia Tallo,
  • Alex Sandro Felisberto Oliveira,
  • Gustavo Saad Silva El Toghlobi,
  • Rafael Augusto Arantes,
  • Rafael Balsimelli,
  • Bruno Kehrwald-Balsimelli,
  • Bianca Lorayne de Almeida Viana,
  • Fernanda Sakata Matuda,
  • Lucas Antonio Duarte Nicolau,
  • Jand Venes Rolim Medeiros,
  • Adriano Caixeta,
  • Murched Omar Taha,
  • Walter José Gomes,
  • Afonso Caricati-Neto,
  • Francisco Sandro Menezes-Rodrigues

DOI
https://doi.org/10.3390/biomedicines12030582
Journal volume & issue
Vol. 12, no. 3
p. 582

Abstract

Read online

Defined as systemic hypotension caused by intense vasodilation due to the loss of systemic vascular resistance, vasoplegic syndrome (VS) is associated with elevated morbidity and mortality in humans. Although vasopressors such as norepinephrine and vasopressin are the first-choice drugs for VS treatment, several other drugs such as methylene blue (MB) can be used as adjuvant therapy including rescue therapy. To develop new pharmacological strategies to reduce the risk of VS, we investigated the effects of treatments with MB (2 mg/kg/IV), omeprazole (OME, 10 mg/kg/IV), and their combination in an animal model of cardiac ischemia–reperfusion (CIR). The ventricular arrhythmia (VA), atrioventricular block (AVB), and lethality (LET) incidence rates caused by CIR (evaluated via ECG) and serum levels of the cardiac lesion biomarkers creatine kinase–MB (CK-MB) and troponin I (TnI) in adult rats pretreated with saline solution 0.9% and submitted to CIR (SS + CIR group) were compared to those pretreated with MB (MB + CIR group), OME (OME + CIR group), or the MB + OME combination (MB + OME + CIR group). The AVB and LET incidence rates in the MB + CIR (100%), OME + CIR (100%), and MB + OME + CIR (100%) groups were significantly higher compared to the SS + CIR group (60%). The serum level of CK-MB in these groups were also significantly higher compared to the SS + CIR group, demonstrating that the treatments before CIR with MB, OME, and MB + OME produced similar effects in relation to cardiac function and the occurrence of lesions. These results demonstrate that the treatment of animals subjected to the CIR protocol with OME produced the same effects promoted by the treatment with MB, which may suggest the possibility of using OME alone or in combination with MB in medical clinics in treatment of VS.

Keywords